Biosenic

BIOS

Company Profile

  • Business description

    Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

  • Contact

    Rue Granbonpre 11
    Batiment H (bte 24)
    Mont-St-Guibert1435
    BEL

    T: +32 493097366

    https://www.biosenic.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    6

Stocks News & Analysis

stocks

Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026

Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks

Cheap ASX energy play boasts strong cash flows and balance sheet

Markets appear overly bearish on the company despite the company having attracting growth options.
stocks

Market overreacts to earnings miss from moated ASX retailer

Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,245.0066.30-0.71%
CAC 407,843.04126.65-1.59%
DAX 4024,273.1289.97-0.37%
Dow JONES (US)45,351.92279.82-0.61%
FTSE 1009,321.4012.200.13%
HKSE25,829.91490.771.94%
NASDAQ21,524.0327.500.13%
Nikkei 22542,807.82174.530.41%
NZX 50 Index13,079.5036.740.28%
S&P 5006,456.2210.69-0.17%
S&P/ASX 2008,972.4071.70-0.79%
SSE Composite Index3,883.5657.801.51%

Market Movers